In the FLAURA trial, osimertinib demonstrated superior efficacy to first and second generation EGFR TKIs, and is now recommended as first-line therapy in advanced EGFR-positive NSCLC [5,6]. Here, EGFR is linked to non-small cell lung carcinoma.